DSPACE
On April 17, 2023, Dr. Carsten Hoff (49) will become the new CEO of the dSPACE group succeeding Martin Goetzeler (60), who is leaving his post at his own request and for personal reasons. To ensure a smooth handover, Martin Goetzeler will continue to be available to the new CEO in an advisory capacity after April 17, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005072/en/
From left to right, dSPACE founder and shareholder Dr. Herbert Hanselmann, Dr. Carsten Hoff and Martin Goetzeler. (Photo: Business Wire)
Dr. Carsten Hoff is a highly experienced manager, who is ideally suited to the tasks ahead at dSPACE. He comes from a research and development-centric background with a degree in electrical engineering and a doctorate in computer science. He has international management experience and is familiar with dSPACE and the company's products.
Dr. Carsten Hoff is currently Managing Director of CLAAS E-Systems. Prior to that, he worked in various management positions at the automotive supplier HELLA. He will use his extensive experience from previous positions to provide strategic impetus for dSPACE and to continue to drive forward the new topics of software-based simulation and validation.
"I am very pleased to be joining the dSPACE company. I am very impressed by the company's development and dSPACE's role in the automotive industry. The values that the family-owned company dSPACE stands for convinced me,” stated Dr. Carsten Hoff.
"Dr. Carsten Hoff, an internationally experienced and technically skilled manager who is very familiar with the current challenges in our target markets is taking the helm – I wish him a good start in the company and with our customers," said Dr. Herbert Hanselmann, founder and shareholder of dSPACE.
"Under Martin Goetzeler's successful leadership, dSPACE has sustainably strengthened its market position by setting a decisive course in terms of consistent portfolio expansion, globalization, and future-oriented structures. By continually expanding future investments and the team, he has succeeded in continuing the great growth rate at a high level of sales in challenging years," said Dr. Herbert Hanselmann, adding, "We regret but respect Martin Goetzeler's decision. I would like to expressly thank him for his important contribution, his extraordinary commitment, and the close cooperation based on trust."
"It has been an exciting five years. The excellent and close cooperation with the entire dSPACE team, our customers and partners, and the shareholder family was the key to success and motivation at all times. I would like to thank everyone very much for this," said Martin Goetzeler. "After a fulfilling professional career, I would like to devote more time to my personal and family tasks and interests in the future. I wish my successor and all dSPACE employees the necessary skills, much success, and all the best for the future," said Goetzeler.
Martin Goetzeler has led the dSPACE company since March 1, 2018. Portfolio expansions in virtual and real simulation and validation to cover market and customer requirements in a timely manner, especially in automated and autonomous driving and in the software-defined vehicle were important milestones during this time. In addition to the great importance of software-in-the-loop simulation in this process, technologies such as AI and cloud are now also being used in the products. At the same time, he systematically built up structures and processes to sustainably secure the strong global growth.
About dSPACE
dSPACE is a leading provider of simulation and validation solutions worldwide for developing networked, autonomous, and electrically powered vehicles. The company's range of end-to-end solutions are used particularly by automotive manufacturers and their suppliers to test the software and hardware components in their new vehicles long before a new model is allowed on the road. Not only is dSPACE a sought-after partner in vehicle development, engineers also rely on our know-how at dSPACE when it comes to aerospace and industrial automation. Our portfolio ranges from end-to-end solutions for simulation and validation to engineering and consulting services as well as training and support. With approximately 2,200 employees worldwide, dSPACE is headquartered in Paderborn, Germany, has three project centers in Germany, and serves customers through regional dSPACE companies in the USA, the UK, France, Japan, China, Croatia, and South Korea.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005072/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom